These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 26272673)

  • 41. Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain.
    Mikkelsen M; Holst PJ; Bukh J; Thomsen AR; Christensen JP
    J Immunol; 2011 Feb; 186(4):2355-64. PubMed ID: 21257961
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Protective immunity of plant-produced African horse sickness virus serotype 5 chimaeric virus-like particles (VLPs) and viral protein 2 (VP2) vaccines in IFNAR
    O'Kennedy MM; Coetzee P; Koekemoer O; du Plessis L; Lourens CW; Kwezi L; du Preez I; Mamputha S; Mokoena NB; Rutkowska DA; Verschoor JA; Lemmer Y
    Vaccine; 2022 Aug; 40(35):5160-5169. PubMed ID: 35902279
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Soluble Version of Nipah Virus Glycoprotein G Delivered by Vaccinia Virus MVA Activates Specific CD8 and CD4 T Cells in Mice.
    Kalodimou G; Veit S; Jany S; Kalinke U; Broder CC; Sutter G; Volz A
    Viruses; 2019 Dec; 12(1):. PubMed ID: 31878180
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Novel simian immunodeficiency virus CTL epitopes restricted by MHC class I molecule Mamu-B*01 are highly conserved for long term in DNA/MVA-vaccinated, SHIV-challenged rhesus macaques.
    Su J; Luscher MA; Xiong Y; Rustam T; Amara RR; Rakasz E; Robinson HL; MacDonald KS
    Int Immunol; 2005 May; 17(5):637-48. PubMed ID: 15824066
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of a linear neutralization domain in the protein VP2 of African horse sickness virus.
    Martínez-Torrecuadrada JL; Casal JI
    Virology; 1995 Jul; 210(2):391-9. PubMed ID: 7542417
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Concomitant type I IFN receptor-triggering of T cells and of DC is required to promote maximal modified vaccinia virus Ankara-induced T-cell expansion.
    Frenz T; Waibler Z; Hofmann J; Hamdorf M; Lantermann M; Reizis B; Tovey MG; Aichele P; Sutter G; Kalinke U
    Eur J Immunol; 2010 Oct; 40(10):2769-77. PubMed ID: 20821729
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Heterologous prime boost vaccination with DNA and recombinant modified vaccinia virus Ankara protects IFNAR(-/-) mice against lethal bluetongue infection.
    Calvo-Pinilla E; Rodríguez-Calvo T; Sevilla N; Ortego J
    Vaccine; 2009 Dec; 28(2):437-45. PubMed ID: 19857449
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Heterologous Combination of ChAdOx1 and MVA Vectors Expressing Protein NS1 as Vaccination Strategy to Induce Durable and Cross-Protective CD8+ T Cell Immunity to Bluetongue Virus.
    Utrilla-Trigo S; Jiménez-Cabello L; Alonso-Ravelo R; Calvo-Pinilla E; Marín-López A; Moreno S; Lorenzo G; Benavides J; Gilbert S; Nogales A; Ortego J
    Vaccines (Basel); 2020 Jun; 8(3):. PubMed ID: 32610561
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Novel Potent IFN-γ-Inducing CD8
    Sangewar N; Waghela SD; Yao J; Sang H; Bray J; Mwangi W
    J Immunol; 2021 Apr; 206(8):1709-1718. PubMed ID: 33762324
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of antigenic regions on VP2 of African horsesickness virus serotype 3 by using phage-displayed epitope libraries.
    Bentley L; Fehrsen J; Jordaan F; Huismans H; du Plessis DH
    J Gen Virol; 2000 Apr; 81(Pt 4):993-1000. PubMed ID: 10725425
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characterization of tubular structures composed of nonstructural protein NS1 of African horsesickness virus expressed in insect cells.
    Maree FF; Huismans H
    J Gen Virol; 1997 May; 78 ( Pt 5)():1077-82. PubMed ID: 9152425
    [TBL] [Abstract][Full Text] [Related]  

  • 52. DNA immunization with 2C FMDV non-structural protein reveals the presence of an immunodominant CD8+, CTL epitope for Balb/c mice.
    Barfoed AM; Rodriguez F; Therrien D; Borrego B; Sobrino F; Kamstrup S
    Antiviral Res; 2006 Dec; 72(3):178-89. PubMed ID: 16890298
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of vaccinia CD8+ T-cell epitopes conserved among vaccinia and variola viruses restricted by common MHC class I molecules, HLA-A2 or HLA-B7.
    Terajima M; Cruz J; Leporati AM; Demkowicz WE; Kennedy JS; Ennis FA
    Hum Immunol; 2006 Jul; 67(7):512-20. PubMed ID: 16829305
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Identification of a dengue virus-specific HLA-A*0201-restricted CD8+ T cell epitope.
    Wen J; Duan Z; Jiang L
    J Med Virol; 2010 Apr; 82(4):642-8. PubMed ID: 20166182
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An intact signal peptide on dengue virus E protein enhances immunogenicity for CD8(+) T cells and antibody when expressed from modified vaccinia Ankara.
    Quinan BR; Flesch IE; Pinho TM; Coelho FM; Tscharke DC; da Fonseca FG
    Vaccine; 2014 May; 32(25):2972-9. PubMed ID: 24726244
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses.
    Snyder JT; Belyakov IM; Dzutsev A; Lemonnier F; Berzofsky JA
    J Virol; 2004 Jul; 78(13):7052-60. PubMed ID: 15194781
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recombinant baculovirus-synthesized African horsesickness virus (AHSV) outer-capsid protein VP2 provides protection against virulent AHSV challenge.
    Roy P; Bishop DH; Howard S; Aitchison H; Erasmus B
    J Gen Virol; 1996 Sep; 77 ( Pt 9)():2053-7. PubMed ID: 8811002
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of a novel, guinea pig-specific IFN-γ ELISPOT assay and characterization of guinea pig cytomegalovirus GP83-specific cellular immune responses following immunization with a modified vaccinia virus Ankara (MVA)-vectored GP83 vaccine.
    Gillis PA; Hernandez-Alvarado N; Gnanandarajah JS; Wussow F; Diamond DJ; Schleiss MR
    Vaccine; 2014 Jun; 32(31):3963-70. PubMed ID: 24856783
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Protective immune responses to the E and NS1 proteins of Murray Valley encephalitis virus in hybrids of flavivirus-resistant mice.
    Hall RA; Brand TN; Lobigs M; Sangster MY; Howard MJ; Mackenzie JS
    J Gen Virol; 1996 Jun; 77 ( Pt 6)():1287-94. PubMed ID: 8683218
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification and characterization of a cross-neutralization epitope of Enterovirus 71.
    Liu CC; Chou AH; Lien SP; Lin HY; Liu SJ; Chang JY; Guo MS; Chow YH; Yang WS; Chang KH; Sia C; Chong P
    Vaccine; 2011 Jun; 29(26):4362-72. PubMed ID: 21501643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.